Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines' common metabolite against captopril.

Mitręga KA, Spałek AM, Nożyński J, Porc M, Stankiewicz M, Krzemiński TF.

PLoS One. 2017 Jun 21;12(6):e0179633. doi: 10.1371/journal.pone.0179633. eCollection 2017.

2.

Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial.

Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, Francis SA, Lumish H, Ghoshhajra BB, Hoffmann U, Appelbaum E, Feng JH, Blankstein R, Steigner M, McConnell JP, Harris W, Antman EM, Jerosch-Herold M, Kwong RY.

Circulation. 2016 Aug 2;134(5):378-91. doi: 10.1161/CIRCULATIONAHA.115.019949.

PMID:
27482002
3.

Educational Case: A 57-year-old man with chest pain.

Aggarwal N, Selvendran S, Vassiliou V.

Oxf Med Case Reports. 2016 Apr 14;2016(4):62-5. doi: 10.1093/omcr/omw008. eCollection 2016 Apr. No abstract available.

4.

Aerobic Training after Myocardial Infarction: Remodeling Evaluated by Cardiac Magnetic Resonance.

Izeli NL, Santos AJ, Crescêncio JC, Gonçalves AC, Papa V, Marques F, Pazin-Filho A, Gallo-Júnior L, Schmidt A.

Arq Bras Cardiol. 2016 Apr;106(4):311-8. doi: 10.5935/abc.20160031. Epub 2016 Mar 8. English, Portuguese.

5.

Adipose-derived mesenchymal stem cells embedded in platelet-rich fibrin scaffolds promote angiogenesis, preserve heart function, and reduce left ventricular remodeling in rat acute myocardial infarction.

Chen YL, Sun CK, Tsai TH, Chang LT, Leu S, Zhen YY, Sheu JJ, Chua S, Yeh KH, Lu HI, Chang HW, Lee FY, Yip HK.

Am J Transl Res. 2015 May 15;7(5):781-803. eCollection 2015.

6.

Innate immune response after acute myocardial infarction and pharmacomodulatory action of tacrolimus in reducing infarct size and preserving myocardial integrity.

Sheu JJ, Sung PH, Leu S, Chai HT, Zhen YY, Chen YC, Chua S, Chen YL, Tsai TH, Lee FY, Chang HW, Ko SF, Yip HK.

J Biomed Sci. 2013 Oct 29;20:82. doi: 10.1186/1423-0127-20-82.

7.

The Right Heart in Congenital Heart Disease, Mechanisms and Recent Advances.

Guihaire J, Haddad F, Mercier O, Murphy DJ, Wu JC, Fadel E.

J Clin Exp Cardiolog. 2012 Jun 15;8(10):1-11.

8.

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW.

Am J Cardiol. 2013 May 15;111(10):1394-400. doi: 10.1016/j.amjcard.2013.01.287. Epub 2013 Feb 27.

9.

Hospital performance measures and 30-day readmission rates.

Stefan MS, Pekow PS, Nsa W, Priya A, Miller LE, Bratzler DW, Rothberg MB, Goldberg RJ, Baus K, Lindenauer PK.

J Gen Intern Med. 2013 Mar;28(3):377-85. doi: 10.1007/s11606-012-2229-8. Epub 2012 Oct 16.

10.

Prevalence and predictors of ventricular remodeling after anterior myocardial infarction in the era of modern medical therapy.

Farah E, Cogni AL, Minicucci MF, Azevedo PS, Okoshi K, Matsubara BB, Zanati SG, Haggeman R, Paiva SA, Zornoff LA.

Med Sci Monit. 2012 May;18(5):CR276-81.

11.

The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.

Cho YR, Kim YD, Park TH, Park K, Park JS, Baek H, Choi SY, Kim KS, Hong TJ, Yang TH, Hwang JY, Park JS, Hur SH, Lee SG.

Trials. 2011 Nov 22;12:247. doi: 10.1186/1745-6215-12-247.

12.

Infarct restraint to limit adverse ventricular remodeling.

Gorman RC, Jackson BM, Burdick JA, Gorman JH.

J Cardiovasc Transl Res. 2011 Feb;4(1):73-81. doi: 10.1007/s12265-010-9244-0. Epub 2010 Dec 15. Review.

13.

Effects of ACE2 inhibition in the post-myocardial infarction heart.

Kim MA, Yang D, Kida K, Molotkova N, Yeo SJ, Varki N, Iwata M, Dalton ND, Peterson KL, Siems WE, Walther T, Cowling RT, Kjekshus J, Greenberg B.

J Card Fail. 2010 Sep;16(9):777-85. doi: 10.1016/j.cardfail.2010.04.002. Epub 2010 May 23.

14.

Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.

Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE.

J Am Coll Cardiol. 2010 Jul 27;56(5):392-406. doi: 10.1016/j.jacc.2010.05.011.

15.

The role of oxidative stress and lipid peroxidation in ventricular remodeling induced by tobacco smoke exposure after myocardial infarction.

Duarte DR, Minicucci MF, Azevedo PS, Matsubara BB, Matsubara LS, Novelli EL, Paiva SA, Zornoff LA.

Clinics (Sao Paulo). 2009;64(7):691-7. doi: 10.1590/S1807-59322009000700014.

16.

Peripheral artery disease: potential role of ACE-inhibitor therapy.

Coppola G, Romano G, Corrado E, Grisanti RM, Novo S.

Vasc Health Risk Manag. 2008;4(6):1179-87. Review.

17.

Coronary bypass surgery with or without surgical ventricular reconstruction.

Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL; STICH Hypothesis 2 Investigators.

N Engl J Med. 2009 Apr 23;360(17):1705-17. doi: 10.1056/NEJMoa0900559. Epub 2009 Mar 29.

18.

Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial.

Dzavík V, Buller CE, Lamas GA, Rankin JM, Mancini GB, Cantor WJ, Carere RJ, Ross JR, Atchison D, Forman S, Thomas B, Buszman P, Vozzi C, Glanz A, Cohen EA, Meciar P, Devlin G, Mascette A, Sopko G, Knatterud GL, Hochman JS; TOSCA-2 Investigators.

Circulation. 2006 Dec 5;114(23):2449-57. Epub 2006 Nov 14.

19.

Hypertension and concomitant diseases: a guide for evidence-based therapy.

Retta TM, Randall OS.

J Natl Med Assoc. 2004 Apr;96(4):450-60. Review.

20.

Myocardial viability: impact on left ventricular dilatation after acute myocardial infarction.

Nijland F, Kamp O, Verhorst PM, de Voogt WG, Bosch HG, Visser CA.

Heart. 2002 Jan;87(1):17-22.

Supplemental Content

Support Center